Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2015 · 10-Q
Revenue$127.00K$127.00K+14.4% vs Q1 2014 Net Income-$7.17M-$7.17MN/M vs Q1 2014 EPS Diluted-$0.33-$0.33N/M vs Q1 2014 Operating Income-$4,847,752N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,979,979N/M Margins · derivedOperating margin-3817.1%−880.5 pt vs Q1 2014
Net margin-5649.1%−2775.4 pt vs Q1 2014
ended Mar 31, 2015 · filed May 5, 2015 · 35 d after period end